CO21 | The strategy on healthcare-associated infections prevention in patients with previous SARS-CoV 2 infection. Analysis of the cost and consumption of antibiotics
M. Lugarà1, D. Birra2, C. Bologna1, D.V. Iula3, R. Piscitelli4, R. Natale5, L.M. Capece5, P. Tirelli1, M. Borrelli5, V. Nuzzo1 | 1Presidio Ospedaliero Del Mare -Unit of General Internal Medicine, Naples, 2Presidio Ospedaliero Del Mare -Unit of General Internal Medicine Naples, 3Presidio Ospedaliero Del Mare, Microbiology Unit, Naples, 4Presidio Ospedaliero Del Mare, Department of Pharmacy, Naples, 5Department of clinical Medicine an d Surgery-Internal Medicine-University Federico II, Naples, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Purpose of the study: Healthcare-associated-infections represent frequent complications of hospital care. Active surveillance activities, prevalence and incidence investigations are fundamental, as a described in PNCAR 2022-2025.
Materials and Methods: the “Ospedale del Mare” showed a 30% increase in super-infections from MDR germs, particular Acinetobacter B. also in Sars-CoV-2 patients. Within 24 hours of hospitalization, patients underwent rectal swab for MDR germs and nasal swab for MRSA.
Results: Comparison between 2021 vs. 2022 showed in 2022 24% increase in positive MRSA nasal swabs in General Medicine (GM), 21% in ICU and 43% in Emergency Medicine (EM). In 2022 there was a 25% increase in positive MDR rectal swabs in GM, 30% in ICU and 41% in EM. Surveillance strategy highlighted an increased rate of MDR germs, particularly Acinetobacter without significant difference in 2022.
Conclusions: Early identification of colonized patients in GM led to 3.4% reduction of meropenem DDD (2021 vs. 2022) and -45% of costs, while for ceftazidime/avibactam -55.3% and -52.4%. In EM, 100% DDD reduction, while in ICU there was a +533% DDD increase, with increased cost by 579%. The cost analysis for all UUOOs for ceftazidime\avibactam showed 19% increase, also due to 14% price reduction. The sub-analysis of the ICU data showed that, despite the increased costs for antibiotic therapy and the number of MDR colonization/infections, the mortality rate lowers from 71.8% in 2021 to 63% in 2022 with an average stay in ICU of 17 days in 2021 rather than 16 days in 2022, showing a slight reduction.
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.